Efficacy and Safety of Avacopan in patients with ANCA-associated vasculitis: A Systematic Review and Meta-analysis
Open Access
- 25 August 2026
- journal article
- review article
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1423
Abstract
Background Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune vasculitis characterized by inflammation of small- to medium-sized blood vessels. While conventional treatments such as glucocorticoids and immunosuppressant improve disease control, they carry a high burden of toxicity. Avacopan, an oral complement 5a receptor inhibitor, has emerged as a potential steroid-sparing therapy. This meta-analysis aimed to evaluate the efficacy and safety of avacopan in patients with AAV. Methods This systematic review and meta-analysis followed PRISMA guidelines. A total of seven randomized controlled trials involving patients with AAV were included. Primary outcomes assessed included clinical efficacy (remission at 26 and 52 weeks, relapse, and vasculitis worsening), glucocorticoid toxicity, safety and tolerability, and organ-specific adverse effects. Pooled odds ratios (ORs) or mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Results Avacopan demonstrated significantly higher remission rates at 52 weeks (OR 1.79; 95% CI: 1.18–2.72; p = 0.006) and lower relapse rates (OR 0.39; 95% CI: 0.21–0.72; p = 0.003) compared to standard care. Steroid-related toxicity was significantly reduced, with lower GTI-AIS and cumulative worsening scores at 13 and 26 weeks. Notably, avacopan reduced infection rates (OR 0.69; p = 0.02) and adverse psychiatric events (OR 0.55; p = 0.03). While other adverse events were numerically lower, they were not statistically significant, indicating a comparable or improved safety profile. Conclusion Avacopan improves long-term clinical outcomes and reduces glucocorticoid-related toxicity in AAV, representing a safer, effective adjunct to standard therapy.Keywords
This publication has 40 references indexed in Scilit:
- Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World SettingKidney International Reports, 2024
- Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring DialysisKidney International Reports, 2023
- Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of AvacopanKidney International Reports, 2023
- Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated VasculitisKidney International Reports, 2021
- Avacopan: First ApprovalDrugs, 2021
- Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated VasculitisACR Open Rheumatology, 2020
- Complement in ANCA-Associated VasculitisSeminars in Nephrology, 2013
- S1. Rituximab for ANCA-associated vasculitis: The experience in the United StatesLa Presse Médicale, 2013
- Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: Comment on the article by Faurschou et alArthritis & Rheumatism, 2012
- Brief Report: Long‐term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2012